Cargando…
Clinical Benefit of Pazopanib in a Patient with Metastatic Chondrosarcoma: A Case Report and Review of the Literature
Chondrosarcoma is a rare malignancy characterized by the production of cartilage matrix, displaying heterogeneous histopathology and clinical behavior. Due to lack of effective treatment for advanced disease, the clinical management of metastatic chondrosarcoma is exceptionally challenging. Chondros...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5837964/ https://www.ncbi.nlm.nih.gov/pubmed/29546033 http://dx.doi.org/10.3389/fonc.2018.00045 |
_version_ | 1783304151043670016 |
---|---|
author | Tsavaris, Onoufrios Economopoulou, Panagiota Kotsantis, Ioannis Reppas, Lazaros Avgerinou, Chrysanthi Spathas, Nikolaos Prevezanou, Maria Psyrri, Amanda |
author_facet | Tsavaris, Onoufrios Economopoulou, Panagiota Kotsantis, Ioannis Reppas, Lazaros Avgerinou, Chrysanthi Spathas, Nikolaos Prevezanou, Maria Psyrri, Amanda |
author_sort | Tsavaris, Onoufrios |
collection | PubMed |
description | Chondrosarcoma is a rare malignancy characterized by the production of cartilage matrix, displaying heterogeneous histopathology and clinical behavior. Due to lack of effective treatment for advanced disease, the clinical management of metastatic chondrosarcoma is exceptionally challenging. Chondrosarcomas harbor molecular abnormalities, such as overexpression of platelet-derived growth factor receptor (PDGFR)-alpha and PDGFR-beta, which are required for cancer development, progression, and metastasis. Pazopanib is a potent and selective multitargeted tyrosine kinase inhibitor, which co-inhibits stem cell growth factor receptor (c-KIT), fibroblast growth factor receptor (FGFR), PDGFR, and vascular endothelial growth factor receptor (VEGFR) and has demonstrated clinical activity in patients with advanced previously treated soft tissue sarcoma. Herein, we describe the unique case of a patient with metastatic chondrosarcoma who derived clinical benefit from pazopanib after first-line chemotherapy failure. |
format | Online Article Text |
id | pubmed-5837964 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-58379642018-03-15 Clinical Benefit of Pazopanib in a Patient with Metastatic Chondrosarcoma: A Case Report and Review of the Literature Tsavaris, Onoufrios Economopoulou, Panagiota Kotsantis, Ioannis Reppas, Lazaros Avgerinou, Chrysanthi Spathas, Nikolaos Prevezanou, Maria Psyrri, Amanda Front Oncol Oncology Chondrosarcoma is a rare malignancy characterized by the production of cartilage matrix, displaying heterogeneous histopathology and clinical behavior. Due to lack of effective treatment for advanced disease, the clinical management of metastatic chondrosarcoma is exceptionally challenging. Chondrosarcomas harbor molecular abnormalities, such as overexpression of platelet-derived growth factor receptor (PDGFR)-alpha and PDGFR-beta, which are required for cancer development, progression, and metastasis. Pazopanib is a potent and selective multitargeted tyrosine kinase inhibitor, which co-inhibits stem cell growth factor receptor (c-KIT), fibroblast growth factor receptor (FGFR), PDGFR, and vascular endothelial growth factor receptor (VEGFR) and has demonstrated clinical activity in patients with advanced previously treated soft tissue sarcoma. Herein, we describe the unique case of a patient with metastatic chondrosarcoma who derived clinical benefit from pazopanib after first-line chemotherapy failure. Frontiers Media S.A. 2018-03-01 /pmc/articles/PMC5837964/ /pubmed/29546033 http://dx.doi.org/10.3389/fonc.2018.00045 Text en Copyright © 2018 Tsavaris, Economopoulou, Kotsantis, Reppas, Avgerinou, Spathas, Prevezanou and Psyrri. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Tsavaris, Onoufrios Economopoulou, Panagiota Kotsantis, Ioannis Reppas, Lazaros Avgerinou, Chrysanthi Spathas, Nikolaos Prevezanou, Maria Psyrri, Amanda Clinical Benefit of Pazopanib in a Patient with Metastatic Chondrosarcoma: A Case Report and Review of the Literature |
title | Clinical Benefit of Pazopanib in a Patient with Metastatic Chondrosarcoma: A Case Report and Review of the Literature |
title_full | Clinical Benefit of Pazopanib in a Patient with Metastatic Chondrosarcoma: A Case Report and Review of the Literature |
title_fullStr | Clinical Benefit of Pazopanib in a Patient with Metastatic Chondrosarcoma: A Case Report and Review of the Literature |
title_full_unstemmed | Clinical Benefit of Pazopanib in a Patient with Metastatic Chondrosarcoma: A Case Report and Review of the Literature |
title_short | Clinical Benefit of Pazopanib in a Patient with Metastatic Chondrosarcoma: A Case Report and Review of the Literature |
title_sort | clinical benefit of pazopanib in a patient with metastatic chondrosarcoma: a case report and review of the literature |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5837964/ https://www.ncbi.nlm.nih.gov/pubmed/29546033 http://dx.doi.org/10.3389/fonc.2018.00045 |
work_keys_str_mv | AT tsavarisonoufrios clinicalbenefitofpazopanibinapatientwithmetastaticchondrosarcomaacasereportandreviewoftheliterature AT economopouloupanagiota clinicalbenefitofpazopanibinapatientwithmetastaticchondrosarcomaacasereportandreviewoftheliterature AT kotsantisioannis clinicalbenefitofpazopanibinapatientwithmetastaticchondrosarcomaacasereportandreviewoftheliterature AT reppaslazaros clinicalbenefitofpazopanibinapatientwithmetastaticchondrosarcomaacasereportandreviewoftheliterature AT avgerinouchrysanthi clinicalbenefitofpazopanibinapatientwithmetastaticchondrosarcomaacasereportandreviewoftheliterature AT spathasnikolaos clinicalbenefitofpazopanibinapatientwithmetastaticchondrosarcomaacasereportandreviewoftheliterature AT prevezanoumaria clinicalbenefitofpazopanibinapatientwithmetastaticchondrosarcomaacasereportandreviewoftheliterature AT psyrriamanda clinicalbenefitofpazopanibinapatientwithmetastaticchondrosarcomaacasereportandreviewoftheliterature |